New York's reliance on Tamiflu for treating bird flu could be a problem, given the potentially limited effectiveness against a pandemic strain of bird flu, according to experts.
Dr. Sean T. Liu highlights the concern that New York's failure to stockpile baloxavir marboxil could be a vulnerability in their strategy against bird flu.
Dr. Howard Zucker emphasizes the importance of having multiple therapeutic options available, especially when facing unknown variables like the evolution of bird flu strains.
Experts worry about the looming threat of the H5N1 flu virus, which has a high mortality rate and could potentially lead to the next pandemic, underscoring the urgency for diversified antiviral stockpiles.
Collection
[
|
...
]